EGR1 decreases the malignancy of human non-small cell lung carcinoma by regulating KRT18 expression

Area of Science:

• Oncology
• Molecular Biology
• Gene Regulation

Background:

• Early Growth Response 1 (EGR1) is a transcription factor with diverse roles in cancer.
• Its specific function in non-small-cell lung carcinoma (NSCLC) requires further elucidation.
• Understanding EGR1's regulatory targets is crucial for developing novel cancer therapies.

Purpose of the Study:

• To investigate the role of EGR1 in non-small-cell lung carcinoma (NSCLC).
• To identify genes regulated by EGR1 that influence NSCLC cell fate and tumor progression.
• To explore the therapeutic potential of EGR1 and its downstream targets in NSCLC.

Main Methods:

• Cellular assays to assess EGR1's effects on cell mobility, migration, and apoptosis.
• Microarray analysis to identify genes with altered mRNA expression in response to EGR1.
• Bioinformatics and promoter analysis to determine EGR1 binding sites and regulatory relationships.
• Immunohistochemistry to evaluate EGR1 and KRT18 protein expression in NSCLC clinical samples.

Main Results:

• EGR1 demonstrated tumor-suppressive functions by arresting cell mobility, inhibiting migration, and inducing apoptosis in NSCLC cells.
• Microarray analysis identified 100 genes, including CDKN1C, CDC27, and PRKDC, whose expression is modulated by EGR1, impacting tumor progression.
• Bioinformatics analysis revealed an EGR1 binding site in the promoter of KRT18, suggesting KRT18 is directly regulated by EGR1.
• In NSCLC clinical cases, EGR1 and KRT18 protein expression were significantly associated, with KRT18 levels linked to lymph node metastasis.

Conclusions:

• EGR1 functions as a tumor suppressor in non-small-cell lung carcinoma.
• EGR1 directly regulates KRT18 expression, contributing to the inhibition of NSCLC development and reduced malignancy.
• The findings highlight a novel EGR1-KRT18 regulatory axis with potential implications for NSCLC treatment.